Cancer Drug Encyclopedia
Approved oncology medications — what they treat, how they work and key safety information.
Relapsed/refractory Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Small Cell Lung Cancer, or Acute Lymphoblastic Leukemia.
Approved for use in oncology care according to FDA-approved indications.
Relapsed/refractory Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Small Cell Lung Cancer, or Acute Lymphoblastic Leukemia.
Relapsed/refractory Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Small Cell Lung Cancer, or Acute Lymphoblastic Leukemia.
Multiple Myeloma and Myelodysplastic Syndromes.
Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML) and Ph+ Acute Lymphoblastic Leukemia (ALL).
Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML) and Ph+ Acute Lymphoblastic Leukemia (ALL).
BRAF V600E/K mutation-positive Melanoma, Non-Small Cell Lung Cancer, Anaplastic Thyroid Cancer, and Colorectal Cancer.
Hodgkin Lymphoma, CD30-expressing T-cell lymphomas, Urothelial Carcinoma, Cervical Cancer, or Diffuse Large B-cell Lymphoma.
Relapsed or refractory B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, or Multiple Myeloma.
Relapsed or refractory B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, or Multiple Myeloma.
ALK-positive and ROS1-positive metastatic Non-Small Cell Lung Cancer.